04:28 AM EDT, 05/31/2024 (MT Newswires) -- Gyre Therapeutics ( GYRE ) said late Thursday that the Chinese National Medical Products Administration approved its subsidiary Gyre Pharmaceuticals' investigational new drug application for F230, its therapeutic candidate for pulmonary arterial hypertension.

In preclinical studies, F230 showed significant decreases in mean pulmonary arterial pressure, right ventricular systolic pressure, right ventricular/left ventricular plus septum and pulmonary artery wall thickness, according to the company.

F230 was licensed from Eisai through Gyre's indirect majority stockholder, GNI Group. The company is also evaluating other disease indications for the product.

Price: 10.08, Change: -0.33, Percent Change: -3.17